remain ew pg given believ fundament
continu limit secularli weak us hpc industri
trend region respons half pg profit
weak organ sale price drive gm squeez pg stock trade
follow disappoint result weak organ sale
growth consensu market expect driven
price pg worst result modern histori bp gross margin
contract yoy outlin note refram us hpc risk earlier
outlook select linger topline/gross margin woe
believ us hpc environ secularli slow pg result support
thesi particularli pg price pressur expect linger
rest calendar
point pg result support cautiou us hpc thesi includ
follow
us hpc price outlook appear worsen evidenc pg
declin unround compani worst result far
back model track believ price pressur linger
particularli us greater competit intens brand
player well pushback larg us brick mortar retail
compet e-commerce/discount player pg lap price
intervent taken last april gillett remain concern pg product
signific price premium see category-at-risk-assess
greater detail creat risk futur price invest may
necessari compani indic would need reinvigor
trend baby/groom
household person unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
continu declin
gross margin pressur becom acut particularli
price inflationari commod environ pg gross margin
declin bp bp net impact price/mix
commod expect price headwind linger next year
pg begin annual commod inflat next quarter
price outlook deterior vs prior forecast
number ep came slightli consensu
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
organ sale consensu market expect
pg segment weight market share trend remain weak bp share
loss line bp bp although pg
indic retail inventori reduct reduc top-line result bp
inter-categori mix hurt overal share underli result subpar
gross/oper profit miss vs consensu driven neg price
corpor expens miss forecast y-o-i ex fx
off-set profit line item report sale actual beat
consensu fx howev off-set weaker expect
gross margin bp consensu unfavor commod
bp neg price bp unfavor geograph mix bp
off-set cost save bp led gross profit miss vs
consensu sg sale came bp consensu mitig
gross margin pressur oper profit miss consensu
lower price ep tweak ep estim
cent reflect modest reduct organ sale growth
coupl lower profit base lower price target
base ep reflect slightli
cautiou top-line outlook greater reinvest risk expect weigh
sentiment
price develop market skew portfolio
still drive weaker top-line growth peer
market share loss
posit chang believ
posit chang put
place pg includ strategi tweak
focu core shift decis make
local level better tie compens
individu perform better execut
valuat look fair pg trade
compress ep see
clear near-term catalyst pg share re-
rate higher given top-line growth forecast
remain mega-cap peer said
risk achiev price
market share vacil currenc
deriv base case scenario
top-line rebound organ sale growth revenu upsid bp
int upsid bp us upsid pg marketing/innov focu drive
market share improv cut forecast drive margin
upsid turn hsd ep growth valuat expand ep
mute sale growth cost-cut drive margin forecast organ sale
growth pg go forward peer rang given
pg premium portfolio develop market skew limit growth weak
consum spend environ expect pg om expand bp
drive msd ep growth appli multipl ep
toward lower-end pg peer group given mute top-line growth
us led topline/margin downsid us bear case scenario play
pricing/volum downsid along bp margin downsid
greater reinvest outsid us bp top-line downsid
bp margin downsid drive mute flat lsd ep growth valuat
contract ep
exhibit bear bull top-line trend stock driver
valu
recap weak organ top-line growth driven deterior
qualiti ep weak organ sale neg price pg core
ep consensu mse howev qualiti weak
disappoint organ sales/pr organ sale growth unround
consensu recent lower market expect
two-year averag growth price deceler
sequenti remain neg second consecut quarter
unround mitig volum mix
sale
sale bp chang
sale
sale
sale bp chang
million except ep
weak top-line perform organ sale growth
consensu market expect unround driven
price unround partial offset volum mix two-year
averag organ sale growth pg call
sever headwind includ bp top-line difficulti saudi arabia egypt
nigeria brazil roughli bp trade inventori reduct bp
gillett price intervent base period pg cite categori
growth in-lin compris lsd develop market
prior msd develop market prior
market share continu declin division weight averag basi market
share perform continu declin yoy pg lose bp share line
bp declin averag
exhibit total global market share division weight averag basi remain weak
segment market share trend sequenti market share trend mix
improv groom bp versu bp babi feminin famili
bp versu bp fabric market share trend
sequenti line bp yoy market share deceler beauti
bp versu bp health bp versu bp
exhibit market share perform segment
weak gross margin perform pg gross margin fell bp yoy
versu bp consensu bp mse product save bp
off-set bp fx bp commod bp
transport cost bp price bp neg product geograph mix
bp reinvest sg sale bp yoy fx
bp headwind overhead agenc fee advertis product bp
bp headwind product reinvest gain
compar year-ago period net om bp bp
 spend percentag sale decreas bp quarter reflect
reduct agenc compens product cost disappointingli underli
profit perform continu weak currenc neutral oper profit
exclud corpor expens yoy declin
exhibit market expens declin pg cut ad agenc product cost
guidanc organ sale low end rang sound like
total sale unchang benefit fx acquisit pg rais
low end ep guidanc prior midpoint
cent consensu mse pg expect core effect tax rate
half point prior
pg acquisit merck consum busi separ pg announc agre
purchas merck kgaa consum health busi cash
repres ev/sal multipl ev/ebitda use merck pro-forma
ebitda merck kgaa cover vincent meunier busi sale
grown last two year attract
vitamin supplement over-the-counter categori brand includ neurobion dolo-
neurobion femibion nasivin seven kytta geograph basi
busi mainli outsid us major sale europ latin america
asia transact expect close end calendar pg
strateg believ deal make sens busi sync pg
portfolio strategi compet daili use categori product solv problem
would fit nice within compani person health care busi one pg core
categori posit side deal provid greater geograph scale
improv pg brand/categori footprint attract over-the-counter categori grow msd
global last yr ii provid strong health care commerci
suppli capabl deep technic masteri said deal needl mover
view given acquir busi repres total sale pg pay high
multipl busi ev/ebitda howev line preced consum
busi deal mark end pg success pgt care joint
ventur teva pharmaceut industri expect termin juli
